Hyperthyroidism: Methimazole Plus L-carnitine and Selenium

Not Applicable

Completed

• Conditions: Hyperthyroidism

• Registration Number: NCT04946123
• Lead Sponsor: Lo.Li.Pharma s.r.l

Brief Summary

The study aims to investigate the benefits of methimazole treatment in patients with hyperthyroidism, associated with supplementation of L-carnitine and Selenium.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-06-15
• Study First Submitted QC: 2021-06-21
• Study First Posted: 2021-06-30
• Study Start: 2021-07-05
• Status Verified: 2025-06
• Primary Completion: 2025-06-04
• Study Completion: 2025-06-04
• Last Update Submitted: 2025-06-04
• Last Update Posted: 2025-06-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Diagnosis of hyperthyroidism requiring therapy with methimazole

Exclusion Criteria

• Drug and alcohol abuse;
• Pregnancy;
• Medically uncontrolled psychiatric conditions;
• Interfering therapies (lithium, interferone, TKI, amiodarone)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Hyperthyroidism symptoms	Change from 6-months supplementation QoL at 12 months of intervention (end of study)	Improvement of the patients' quality of life through questionnaire

Secondary Outcome Measures

Name	Time	Method
TRAb	Four time points: baseline; after 3 months of supplementation; after 6 months of supplementation; end of the study (12 months)	Change in serum TRAb (TSH receptor antibodies)
TSH	Four time points: baseline; after 3 months of supplementation; after 6 months of supplementation; end of the study (12 months)	Change in serum TSH (Thyroid stimulating hormone)

Trial Locations

Locations (1)

Azienda Ospedaliero-Universitaria Città della scienza e degli studi di Torino; 🇮🇹 Torino, Italy